Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
6,945,924
-
Share change
-
-1,294,777
-
Total reported value
-
$14,866,527
-
Put/Call ratio
-
46%
-
Price per share
-
$2.14
-
Number of holders
-
59
-
Value change
-
-$19,573,439
-
Number of buys
-
38
-
Number of sells
-
26
Institutional Holders of CATABASIS PHARMACEUTICALS IN - COM NEW as of Q4 2020
As of 31 Dec 2020,
CATABASIS PHARMACEUTICALS IN - COM NEW was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,945,924 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Ikarian Capital, LLC, MORGAN STANLEY, Eversept Partners, LP, STATE STREET CORP, Samsara BioCapital, LLC, NORTHERN TRUST CORP, GEODE CAPITAL MANAGEMENT, LLC, and Opaleye Management Inc..
This page lists
59
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.